The Landscape of Targeted Therapies in TNBC

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Triple negative breast cancer (TNBC) is the most aggressive subtype, with poor clinical outcomes and limited survival for metastatic patients.
• Chemotherapy is the primary treatment, but targeted therapies like PARP inhibitors and immune checkpoint inhibitors are emerging.
• Tumor heterogeneity and clonal evolution contribute to treatment resistance, necessitating advanced therapeutic approaches.

Purpose of the Study:

• To review current knowledge on the molecular profiles of TNBC.
• To explore the clinical applications of these molecular insights in TNBC treatment.
• To discuss the role of precision medicine in tailoring therapies for TNBC.

Main Methods:

• Literature review of current research on TNBC molecular characteristics.
• Analysis of emerging targeted therapies and their mechanisms.
• Discussion of the impact of next-generation sequencing and molecular markers in clinical practice.

Main Results:

• TNBC exhibits significant molecular heterogeneity and clonal evolution, leading to treatment resistance.
• Novel therapeutic agents are under investigation, with some already integrated into treatment paradigms.
• Precision medicine approaches, guided by molecular markers, are increasingly important for TNBC management.

Conclusions:

• Understanding TNBC's molecular profile is crucial for developing effective treatments.
• Targeted therapies and precision medicine offer promising avenues for improving patient outcomes.
• Continued research into TNBC's molecular landscape is essential for advancing clinical practice.